Phaseline

Targets › PRLR

PRLR (Prolactin receptor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jul 2028.

This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. (UniProt, P16471)

Open in Phaseline: the race on PRLR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbsciABS-201
IgG1 monoclonal antibody targeting prolactin receptor (PRLR)
PRLRPhase 1Androgenetic Alopecia (AGA)Jul 2028

Conditions

Androgenetic Alopecia (AGA) (1)

Modalities

small molecule (1)

Companies

Absci (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.